CytoDyn's Net Loss Widens to $5.54M Amid R&D Spend, Cash Drains

TL;DR

**CYDY is burning cash and its R&D expenses are back in the red, making it a risky bet for any short-term upside.**

AI Summary

CytoDyn Inc. reported a net loss of $5.54 million for the three months ended August 31, 2025, a significant decline from the net income of $19.23 million in the same period of 2024. This shift was primarily driven by a change in research and development expenses, which increased to $3.23 million in Q3 2025 from a gain of $24.05 million in Q3 2024 due to a one-time return of clinical expenses. The company's cash and cash equivalents decreased by 22.4% from $11.90 million on May 31, 2025, to $9.33 million on August 31, 2025. Total current assets fell by 25.4% to $13.35 million, while total liabilities remained high at $112.99 million. The accumulated deficit grew to $893.33 million, and the total stockholders' deficit worsened to $(99.51) million. The company continues to operate on a going concern basis, dependent on securing additional capital and achieving regulatory approval for leronlimab.

Why It Matters

CytoDyn's deepening net loss and dwindling cash reserves raise significant red flags for investors, signaling continued financial instability and a high reliance on future capital raises. The substantial accumulated deficit of $893.33 million and the going concern warning underscore the precarious position of the company, which could impact its ability to fund critical leronlimab clinical trials and retain employees. For customers and the broader market, the slow progress towards regulatory approval for leronlimab means potential treatments remain distant, while competitors in the biotechnology space may gain an advantage by bringing their therapies to market faster.

Risk Assessment

Risk Level: high — CytoDyn faces a high risk level due to its significant net loss of $5.54 million for the quarter, a substantial accumulated deficit of $893.33 million, and a 22.4% decrease in cash and cash equivalents to $9.33 million. The company explicitly states 'substantial doubt about the Company's ability to continue as a going concern,' indicating severe financial distress and reliance on future capital raises.

Analyst Insight

Investors should exercise extreme caution and consider avoiding CYDY given the explicit 'going concern' warning and significant cash burn. Monitor future capital raises and regulatory milestones for leronlimab, but be aware of the high dilution risk and the company's history of losses.

Financial Highlights

total Assets

$13.48M

total Debt

$112.99M

net Income

-$5.54M

eps

-$0.00

cash Position

$9.33M

Key Numbers

• $5.54M — Net Loss (for the three months ended August 31, 2025, compared to $19.23M net income in 2024)
• $9.33M — Cash and Cash Equivalents (as of August 31, 2025, down from $11.90M on May 31, 2025)
• $893.33M — Accumulated Deficit (as of August 31, 2025, indicating significant historical losses)
• $3.23M — Research and Development Expenses (for the three months ended August 31, 2025, compared to a gain of $24.05M in 2024)
• $112.99M — Total Liabilities (as of August 31, 2025, remaining high)
• 1,259,753 thousand — Common Shares Outstanding (as of September 30, 2025)
• 22.4% — Decrease in Cash and Cash Equivalents (from May 31, 2025, to August 31, 2025)
• 25.4% — Decrease in Total Current Assets (from May 31, 2025, to August 31, 2025)

Key Players & Entities

• CytoDyn Inc. (company) — registrant
• SEC (regulator) — Securities and Exchange Commission
• leronlimab (product) — product candidate
• U.S. Food and Drug Administration (regulator) — FDA
• FASB (regulator) — Financial Accounting Standards Board
• Bloomberg (company) — publisher

FAQ

Risk Factors

• Substantial Accumulated Deficit and Going Concern [high — financial]: The company has an accumulated deficit of $893.33 million as of August 31, 2025. This, coupled with a net loss of $5.54 million for the quarter and a significant decrease in cash, raises substantial doubt about the company's ability to continue as a going concern.
• Declining Cash and Current Assets [high — financial]: Cash and cash equivalents decreased by 22.4% to $9.33 million from May 31, 2025, to August 31, 2025. Total current assets also fell by 25.4% to $13.35 million, indicating a tightening liquidity position.
• High Total Liabilities [high — financial]: Total liabilities remain substantial at $112.99 million as of August 31, 2025. This high level of debt, combined with a negative stockholders' deficit of $(99.51) million, presents a significant financial risk.
• Dependence on Leronlimab Regulatory Approval [high — regulatory]: The company's future success is heavily dependent on obtaining regulatory approval for its product candidate, leronlimab. Any delays or failures in the regulatory process pose a significant risk to the company's viability.
• Volatile R&D Expenses [medium — operational]: Research and development expenses can be highly variable, as demonstrated by the swing from a $24.05 million gain in Q3 2024 (due to a one-time return of clinical expenses) to $3.23 million in expenses in Q3 2025. This unpredictability can impact financial planning.
• Negative Stockholders' Deficit [high — financial]: The total stockholders' deficit worsened to $(99.51) million as of August 31, 2025. This indicates that the company's liabilities exceed its assets, a precarious financial position.

Industry Context

CytoDyn operates in the highly competitive biotechnology sector, focusing on the development of novel antibody-based therapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on clinical trial outcomes and market adoption of new treatments for unmet medical needs.

Regulatory Implications

The company's primary product candidate, leronlimab, requires successful navigation of the FDA approval process. Any setbacks or delays in regulatory review for its intended indications could severely impact the company's financial health and future operations.

What Investors Should Do

1. Monitor leronlimab's clinical trial progress and regulatory submission status closely, as this is the primary value driver.
2. Assess the company's ability to secure additional funding, given the declining cash reserves and ongoing operational losses.
3. Evaluate the sustainability of the current cash burn rate against available cash and potential future financing events.
4. Understand the implications of the substantial accumulated deficit and negative stockholders' equity on future financing and strategic options.

Key Dates

• 2025-08-31: End of Q3 2025 reporting period — Reported a net loss of $5.54 million and a decrease in cash to $9.33 million, highlighting ongoing financial challenges.
• 2025-05-31: End of Q2 2025 reporting period — Cash and cash equivalents stood at $11.90 million, and total current assets were $17.88 million, providing a baseline for recent declines.
• 2024-08-31: End of Q3 2024 reporting period — Reported a net income of $19.23 million, largely due to a one-time return of clinical expenses which significantly impacted R&D costs.

Glossary

Accumulated deficit

The cumulative net losses of a company over its lifetime that have not been offset by net income. (Indicates the company's significant historical unprofitability, standing at $893.33 million as of August 31, 2025.)

Going concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. (The company's financial condition raises substantial doubt about its ability to continue as a going concern, necessitating reliance on future capital and regulatory approvals.)

Leronlimab

CytoDyn's product candidate, a humanized monoclonal antibody targeting the CCR5 receptor, being developed for various therapeutic indications. (The company's primary focus and future prospects are contingent on the successful clinical development and regulatory approval of leronlimab.)

CCR5 receptor

A C-C chemokine receptor type 5, implicated in immune-mediated illnesses and viral entry. (The target of CytoDyn's leronlimab, central to the company's research and development strategy.)

Stockholders' deficit

The amount by which a company's liabilities exceed its total assets, resulting in a negative equity position. (Highlights the company's negative net worth, with a deficit of $(99.51) million as of August 31, 2025.)

Monoclonal antibody

A type of protein made in a laboratory that can bind to specific targets in the body, such as cancer cells or viruses. (Describes the nature of leronlimab, the company's core product candidate.)

Year-Over-Year Comparison

Compared to the prior year's period, CytoDyn has shifted from a net income of $19.23 million to a net loss of $5.54 million. This dramatic change was driven by a significant swing in R&D expenses, from a large gain in the prior year to substantial expenses in the current period. Cash reserves have also decreased by 22.4%, and total current assets by 25.4%, indicating a worsening financial position and increased reliance on external capital.

Key Financial Figures

• $0.001 — shares outstanding of the registrant's $0.001 par value common stock. Table of Cont

Filing Documents

• cydy-20250831x10q.htm (10-Q) — 1271KB
• cydy-20250831xex31d1.htm (EX-31.1) — 9KB
• cydy-20250831xex31d2.htm (EX-31.2) — 9KB
• cydy-20250831xex32.htm (EX-32) — 7KB
• 0001104659-25-098552.txt ( ) — 5638KB
• cydy-20250831.xsd (EX-101.SCH) — 44KB
• cydy-20250831_cal.xml (EX-101.CAL) — 40KB
• cydy-20250831_def.xml (EX-101.DEF) — 174KB
• cydy-20250831_lab.xml (EX-101.LAB) — 328KB
• cydy-20250831_pre.xml (EX-101.PRE) — 272KB
• cydy-20250831x10q_htm.xml (XML) — 1007KB

Financial Information

PART I Financial Information 3

CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS 3

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 20

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 27

CONTROLS AND PROCEDURES

ITEM 4. CONTROLS AND PROCEDURES 27

Other Information

PART II Other Information 28

LEGAL PROCEEDINGS

ITEM 1. LEGAL PROCEEDINGS 28

RISK FACTORS

ITEM 1A. RISK FACTORS 28

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 28

EXHIBITS

ITEM 6. EXHIBITS 29 2 Table of Contents

Financial Information

PART I. Financial Information

Consolidated Financial Statements

Item 1. Consolidated Financial Statements CytoDyn Inc. Consolidated Balance Sheets (Unaudited, in thousands, except par value) August 31, 2025 May 31, 2025 Assets Current assets: Cash and cash equivalents $ 9,332 $ 11,903 Prepaid expenses 560 252 Prepaid service fees 3,458 3,723 Other receivables — 2,000 Total current assets 13,350 17,878 Other non-current assets 133 169 Total assets $ 13,483 $ 18,047 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable $ 14,175 $ 14,692 Accrued liabilities and compensation 2,823 2,206 Accrued interest on convertible notes 16,577 18,151 Accrued dividends on convertible preferred stock 8,642 8,269 Convertible notes payable, net 27,200 27,200 Total current liabilities 69,417 70,518 Other liabilities (Note 9) 43,571 43,571 Total liabilities 112,988 114,089 Commitments and Contingencies (Note 9) Stockholders' deficit: Preferred stock, $ 0.001 par value; 5,000 shares authorized: Series B convertible preferred stock, $ 0.001 par value; 400 authorized; 19 issued and outstanding at August 31, 2025 and May 31, 2025 — — Series C convertible preferred stock, $ 0.001 par value; 8 authorized; 6 issued and outstanding at August 31, 2025 and May 31, 2025 — — Series D convertible preferred stock, $ 0.001 par value; 12 authorized; 9 issued and outstanding at August 31, 2025 and May 31, 2025 — — Common stock, $ 0.001 par value; 1,750,000 shares authorized; 1,257,045 and 1,249,460 issued, and 1,256,759 and 1,249,174 outstanding at August 31, 2025 and May 31, 2025, respectively 1,257 1,249 Treasury stock, $ 0.001 par value; 286 shares at August 31, 2025 and May 31, 2025 — — Additional paid-in capital 792,564 790,495 Accumulated deficit ( 893,326 ) ( 887,786 ) Total stockholders' deficit ( 99,505 ) ( 96,042 ) Total liabilities and stockholders' deficit $ 13,483 $ 18,047 See accompanying note

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS AS OF AUGUST 31, 2025 (Unaudited) Note 1. Organization CytoDyn Inc. (together with its wholly owned subsidiary, the "Company") was originally incorporated under the laws of Colorado on May 2, 2002, under the name RexRay Corporation and, effective August 27, 2015, reincorporated under the laws of Delaware. The Company is a clinical-stage biotechnology company focused on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 ("CCR5"). The Company investigates leronlimab as a viral entry inhibitor believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. The CCR5 receptor is believed to be implicated in immune-mediated illnesses. Leronlimab is being studied in solid tumors in oncology. The Company also strategically works with select partners to explore leronlimab's potential benefits in certain inflammatory diseases. Note 2. Summary of Significant Accounting Policies Basis of presentation The unaudited consolidated financial statements include the accounts of CytoDyn Inc. and its wholly owned subsidiary, CytoDyn Operations Inc. All intercompany transactions and balances are eliminated in consolidation. The consolidated financial statements reflect all normal recurring adjustments which are, in the opinion of management, necessary for a fair statement of the results of operations for the interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP" or "GAAP") have been omitted in accordance with the rules and regulations of the United States Securities and Exchange Commission ("SEC") . The interim financial information and notes thereto should be read in conjunctio

View Full Filing

View this 10-Q filing on SEC EDGAR